Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent ...

Annual Report/MiscellaneousMEDICLIN ends successful 2024 financial year 28.03.2025 / 10:24 CET/CESTThe issuer is solely responsible for the content of this announcement.Offenburg, March 28, ...

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into a binding agreement to partner with L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A ...

Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging ...

Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 ...

Annual Results/Annual ReportSuccessful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia ...